Analyst Ratings for [PFE] Pfizer, Inc.

12/10/24	Resumed	Neutral	X
PFE Pfizer BofA Securities
$29
11/15/24	Initiated	Underperform	X
PFE Pfizer Wolfe Research
$25
10/25/24	Resumed	Neutral	X
PFE Pfizer Citigroup
$30
10/17/24	Initiated	Mkt Perform	X
PFE Pfizer Bernstein
$32
8/7/24	Upgrades	Neutral Outperform	X
PFE Pfizer Daiwa Securities
3/22/24	Downgrades	Buy Hold	X
PFE Pfizer Argus
2/23/24	Initiated	Buy	X
PFE Pfizer Guggenheim
$36
1/4/24	Downgrades	Outperform Mkt Perform	X
PFE Pfizer TD Cowen
$32
10/20/23	Resumed	Neutral	X
PFE Pfizer UBS
$36 $34
10/16/23	Upgrades	Hold Buy	X
PFE Pfizer Jefferies
$38 $39
7/17/23	Reiterated	Neutral	X
PFE Pfizer JP Morgan
$45 $41
7/14/23	Initiated	Buy	X
PFE Pfizer HSBC Securities
$50
6/29/23	Downgrades	Outperform Neutral	X
PFE Pfizer Credit Suisse
$47 $40
5/11/23	Downgrades	Outperform Neutral	X
PFE Pfizer Daiwa Securities
$38
3/6/23	Initiated	Hold	X
PFE Pfizer Jefferies
$43
2/7/23	Upgrades	Neutral Outperform	X
PFE Pfizer Daiwa Securities
$51
1/26/23	Downgrades	Buy Neutral	X
PFE Pfizer UBS
$55 $47
1/17/23	Downgrades	Overweight Eq Weight	X
PFE Pfizer Wells Fargo
$54 $50
1/4/23	Downgrades	Buy Neutral	X
PFE Pfizer BofA Securities
$60
12/13/22	Upgrades	Neutral Buy	X
PFE Pfizer Goldman
$47 $60
11/18/22	Initiated	Outperform	X
PFE Pfizer Credit Suisse
$55
5/23/22	Initiated	Mkt Perform	X
PFE Pfizer SVB Leerink
$55
1/5/22	Upgrades	Neutral Buy	X
PFE Pfizer BofA Securities
$59 $70
1/3/22	Reiterated	Mkt Perform	X
PFE Pfizer Bernstein
$44 $65
12/20/21	Reiterated	Outperform	X
PFE Pfizer Cowen
$56 $70
12/17/21	Initiated	Neutral	X
PFE Pfizer Goldman
$51
12/13/21	Upgrades	Neutral Buy	X
PFE Pfizer UBS
$52 $60
12/9/21	Initiated	Overweight	X
PFE Pfizer Wells Fargo
$60
11/19/21	Initiated	Outperform	X
PFE Pfizer BMO Capital Markets
$60
7/27/21	Resumed	Buy	X
PFE Pfizer Truist
$43
5/6/21	Downgrades	Buy Neutral	X
PFE Pfizer Mizuho
$42
4/7/21	Resumed	Sector Perform	X
PFE Pfizer RBC Capital Mkts
$42
2/4/21	Upgrades	Hold Buy	X
PFE Pfizer DZ Bank
$41
7/30/19	Downgrades	Buy Neutral	X
PFE Pfizer BofA/Merrill
7/30/19	Downgrades	Overweight Eq-Weight	X
PFE Pfizer Morgan Stanley
$48 $40
6/4/19	Resumed	Overweight	X
PFE Pfizer Morgan Stanley
$48
2/20/19	Resumed	Neutral	X
PFE Pfizer Citigroup
$41
1/31/19	Upgrades	Hold Buy	X
PFE Pfizer Argus
1/31/19	Upgrades	Neutral Outperform	X
PFE Pfizer Credit Suisse
1/23/19	Downgrades	Buy Neutral	X
PFE Pfizer UBS
12/11/18	Downgrades	Overweight Neutral	X
PFE Pfizer JP Morgan
11/1/18	Downgrades	Outperform Mkt Perform	X
PFE Pfizer BMO Capital Markets
6/8/18	Initiated	Overweight	X
PFE Pfizer Cantor Fitzgerald
$45
4/5/18	Downgrades	Overweight Eq Weight	X
PFE Pfizer Barclays
$41 $38
1/29/18	Reiterated	Hold	X
PFE Pfizer SunTrust
$33 $40

PFE Pfizer, Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines, as well as products for consumer healthcare. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.